JP2019531068A5 - - Google Patents

Download PDF

Info

Publication number
JP2019531068A5
JP2019531068A5 JP2019512750A JP2019512750A JP2019531068A5 JP 2019531068 A5 JP2019531068 A5 JP 2019531068A5 JP 2019512750 A JP2019512750 A JP 2019512750A JP 2019512750 A JP2019512750 A JP 2019512750A JP 2019531068 A5 JP2019531068 A5 JP 2019531068A5
Authority
JP
Japan
Prior art keywords
domain
fusion molecule
gene
hepatocyte
dna binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019512750A
Other languages
English (en)
Japanese (ja)
Other versions
JP7256739B2 (ja
JP2019531068A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/050446 external-priority patent/WO2018049009A2/en
Publication of JP2019531068A publication Critical patent/JP2019531068A/ja
Publication of JP2019531068A5 publication Critical patent/JP2019531068A5/ja
Priority to JP2023057789A priority Critical patent/JP2023082133A/ja
Application granted granted Critical
Publication of JP7256739B2 publication Critical patent/JP7256739B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019512750A 2016-09-07 2017-09-07 肝臓遺伝子のモジュレーション Active JP7256739B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023057789A JP2023082133A (ja) 2016-09-07 2023-03-31 肝臓遺伝子のモジュレーション

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662384428P 2016-09-07 2016-09-07
US62/384,428 2016-09-07
PCT/US2017/050446 WO2018049009A2 (en) 2016-09-07 2017-09-07 Modulation of liver genes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023057789A Division JP2023082133A (ja) 2016-09-07 2023-03-31 肝臓遺伝子のモジュレーション

Publications (3)

Publication Number Publication Date
JP2019531068A JP2019531068A (ja) 2019-10-31
JP2019531068A5 true JP2019531068A5 (enExample) 2020-10-15
JP7256739B2 JP7256739B2 (ja) 2023-04-12

Family

ID=61281860

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019512750A Active JP7256739B2 (ja) 2016-09-07 2017-09-07 肝臓遺伝子のモジュレーション
JP2023057789A Withdrawn JP2023082133A (ja) 2016-09-07 2023-03-31 肝臓遺伝子のモジュレーション

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023057789A Withdrawn JP2023082133A (ja) 2016-09-07 2023-03-31 肝臓遺伝子のモジュレーション

Country Status (6)

Country Link
US (2) US10960085B2 (enExample)
EP (1) EP3509645A4 (enExample)
JP (2) JP7256739B2 (enExample)
AU (1) AU2017324462B2 (enExample)
CA (1) CA3035534A1 (enExample)
WO (1) WO2018049009A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110214184B (zh) 2016-12-01 2024-07-02 桑格摩生物治疗股份有限公司 τ蛋白调节剂以及用于其递送的方法和组合物
US11820728B2 (en) 2017-04-28 2023-11-21 Acuitas Therapeutics, Inc. Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2019067875A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE
WO2020010186A1 (en) * 2018-07-06 2020-01-09 Derek Klarin Pcsk9 variants
MX2021001070A (es) * 2018-07-31 2021-05-27 Intellia Therapeutics Inc Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1).
EP3852911B1 (en) 2018-09-21 2025-01-22 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes
IL326834A (en) 2018-10-02 2026-04-01 Sangamo Therapeutics Inc Artificial zinc finger protein transcription factors repressing mapt expression for the prevention and/or treatment of tauopathies
KR20210069692A (ko) * 2018-10-02 2021-06-11 상가모 테라퓨틱스, 인코포레이티드 조작된 유전자 조정제
CA3116576A1 (en) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
JP7578590B2 (ja) 2018-10-18 2024-11-06 インテリア セラピューティクス，インコーポレーテッド 第ｉｘ因子を発現するための組成物及び方法
EP3898661A1 (en) * 2018-12-21 2021-10-27 Precision BioSciences, Inc. Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
PL3908568T3 (pl) 2019-01-11 2024-12-02 Acuitas Therapeutics, Inc. Lipidy do dostarczania środków czynnych w nanocząstkach lipidowych
CN113710693B (zh) 2019-02-25 2025-07-15 马萨诸塞大学 Dna结合结构域反式激活因子及其用途
WO2020247452A1 (en) 2019-06-04 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
US12521451B2 (en) 2019-11-08 2026-01-13 Regeneron Pharmaceuticals, Inc. CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy
CN115362256A (zh) * 2020-02-07 2022-11-18 因特利亚治疗公司 用于激肽释放酶（klkb1）基因编辑的组合物和方法
EP4099821A1 (en) * 2020-02-07 2022-12-14 Regeneron Pharmaceuticals, Inc. <smallcaps/>? ? ?klkb1? ? ? ? ?non-human animals comprising a humanizedlocus and methods of use
KR20230051172A (ko) 2020-07-16 2023-04-17 아퀴타스 테라퓨틱스 인크. 지질 나노 입자에 사용하기 위한 양이온성 지질
EP4185303A4 (en) * 2020-07-24 2024-10-30 University of Massachusetts Dna-binding domain transactivators and uses thereof
KR20250099412A (ko) 2020-11-12 2025-07-01 프리시젼 바이오사이언시스 인코포레이티드 디스트로핀 유전자 내의 인식 서열에 대해 특이성을 갖는 조작된 메가뉴클레아제
WO2022119873A1 (en) * 2020-12-01 2022-06-09 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
WO2022256655A2 (en) 2021-06-04 2022-12-08 Arbor Biotechnologies, Inc. Gene editing systems comprising an rna guide targeting lactate dehydrogenase a (ldha) and uses thereof
WO2023039447A2 (en) * 2021-09-08 2023-03-16 Flagship Pioneering Innovations Vi, Llc Serpina-modulating compositions and methods
WO2023114943A2 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
EP4490294A4 (en) * 2022-03-11 2026-03-18 Epicrispr Biotechnologies Inc GENETIC MODULATION SYSTEMS AND METHODS FOR TREATING LIVER DISEASE
CN119998446A (zh) 2022-06-07 2025-05-13 斯克里贝治疗公司 用于靶向pcsk9的组合物和方法
WO2024206555A1 (en) 2023-03-29 2024-10-03 Scribe Therapeutics Inc. Compositions and methods for the targeting of pcsk9
WO2024229020A2 (en) * 2023-05-01 2024-11-07 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of pcsk9 expression

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
JP4012243B2 (ja) 1994-01-18 2007-11-21 ザ スクリップス リサーチ インスティチュート 亜鉛フィンガータンパク質誘導体およびそのための方法
US6242568B1 (en) 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
CA2196419C (en) 1994-08-20 2007-08-21 Yen Choo Improvements in or relating to binding proteins for recognition of dna
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
GB2338237B (en) 1997-02-18 2001-02-28 Actinova Ltd In vitro peptide or protein expression library
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
DE69942334D1 (de) 1998-03-02 2010-06-17 Massachusetts Inst Technology Poly-zinkfinger-proteine mit verbesserten linkern
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6503717B2 (en) 1999-12-06 2003-01-07 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
AU2001250774B2 (en) 2000-02-08 2005-01-27 Sangamo Biosciences, Inc. Cells expressing zinc finger proteins for drug discovery
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
EP1276859B1 (en) 2000-04-28 2007-02-07 Sangamo Biosciences Inc. Targeted modification of chromatin structure
AU2001257331A1 (en) 2000-04-28 2001-11-12 Sangamo Biosciences, Inc. Methods for designing exogenous regulatory molecules
AU2001263155A1 (en) 2000-05-16 2001-11-26 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
US7029847B2 (en) 2000-05-16 2006-04-18 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
ATE360361T1 (de) 2000-09-28 2007-05-15 Sangamo Biosciences Inc Kernumprogrammierung bei iswi und ähnlichen chromatinremodellierenden atpasen
US6919204B2 (en) 2000-09-29 2005-07-19 Sangamo Biosciences, Inc. Modulation of gene expression using localization domains
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
ATE347593T1 (de) 2002-01-23 2006-12-15 Univ Utah Res Found Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen
EP1504092B2 (en) 2002-03-21 2014-06-25 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
US9447434B2 (en) 2002-09-05 2016-09-20 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7253273B2 (en) 2004-04-08 2007-08-07 Sangamo Biosciences, Inc. Treatment of neuropathic pain with zinc finger proteins
KR20070060115A (ko) 2004-09-16 2007-06-12 상가모 바이오사이언스 인코포레이티드 단백질 생산을 위한 조성물 및 방법
EP2027262B1 (en) 2006-05-25 2010-03-31 Sangamo Biosciences Inc. Variant foki cleavage half-domains
US7951925B2 (en) 2006-05-25 2011-05-31 Sangamo Biosciences, Inc. Methods and compositions for gene inactivation
EP2142217B1 (en) 2007-03-27 2014-11-05 Merck Sharp & Dohme Corp. Method for detecting autoprocessed, secreted pcsk9
US8110379B2 (en) 2007-04-26 2012-02-07 Sangamo Biosciences, Inc. Targeted integration into the PPP1R12C locus
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
CA2720903C (en) 2008-04-14 2019-01-15 Sangamo Biosciences, Inc. Linear donor constructs for targeted integration
US9617548B2 (en) 2008-04-22 2017-04-11 Vib Vzw Liver-specific nucleic acid regulatory elements and methods and use thereof
JP5908725B2 (ja) 2008-08-22 2016-04-26 サンガモ バイオサイエンシーズ， インコーポレイテッド 標的一本鎖開裂および標的組込みのための方法、並びに組成物
EP3156494B8 (en) * 2008-12-04 2018-09-19 Sangamo Therapeutics, Inc. Genome editing in rats using zinc-finger nucleases
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
CA2769262C (en) * 2009-07-28 2019-04-30 Sangamo Biosciences, Inc. Methods and compositions for treating trinucleotide repeat disorders
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
JP6137596B2 (ja) 2010-02-08 2017-05-31 サンガモ セラピューティクス， インコーポレイテッド 遺伝子操作された切断ハーフドメイン
US9255259B2 (en) 2010-02-09 2016-02-09 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
US9567573B2 (en) * 2010-04-26 2017-02-14 Sangamo Biosciences, Inc. Genome editing of a Rosa locus using nucleases
AU2011256838B2 (en) 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
CA2805442C (en) 2010-07-21 2020-05-12 Sangamo Biosciences, Inc. Methods and compositions for modification of an hla locus
EP2627665B1 (en) 2010-10-12 2015-12-16 The Children's Hospital Of Philadelphia Methods and compositions for treating hemophilia B
EP2758529B1 (en) 2011-09-21 2019-03-20 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression
US9222105B2 (en) 2011-10-27 2015-12-29 Sangamo Biosciences, Inc. Methods and compositions for modification of the HPRT locus
WO2013074999A1 (en) 2011-11-16 2013-05-23 Sangamo Biosciences, Inc. Modified dna-binding proteins and uses thereof
CA2865011C (en) * 2012-02-29 2021-06-15 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
CA2871524C (en) * 2012-05-07 2021-07-27 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration of transgenes
HUE051612T2 (hu) 2012-07-11 2021-03-01 Sangamo Therapeutics Inc Eljárások és készítmények lizoszomális tárolási betegségek kezelésére
EP2890780B8 (en) 2012-08-29 2020-08-19 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
DK2911687T3 (da) 2012-10-26 2019-05-13 Univ Brussel Vrije Vektor til levermålrettet genterapi af hæmofili og fremgangsmåder og anvendelse deraf
CA2892448A1 (en) 2012-12-05 2014-06-12 Sangamo Biosciences, Inc. Methods and compositions for regulation of metabolic disorders
KR102955556B1 (ko) 2012-12-12 2026-04-22 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
IL308158A (en) 2012-12-17 2023-12-01 Harvard College Rna-guided human genome engineering
CN105263312A (zh) * 2013-04-05 2016-01-20 美国陶氏益农公司 用于在植物基因组内整合外源序列的方法和组合物
EP2997146A4 (en) 2013-05-15 2017-04-26 Sangamo BioSciences, Inc. Methods and compositions for treatment of a genetic condition
EP3603679B1 (en) 2013-06-04 2022-08-10 President and Fellows of Harvard College Rna-guided transcriptional regulation
JP6738728B2 (ja) 2013-06-17 2020-08-19 ザ・ブロード・インスティテュート・インコーポレイテッド 肝臓ターゲティングおよび治療のためのＣＲＩＳＰＲ−Ｃａｓ系、ベクターおよび組成物の送達および使用
MX367083B (es) * 2013-06-27 2019-08-05 Roche Innovation Ct Copenhagen As Oligomeros antisentido y conjugados con diana en la proteina-convertasa subtilisina/kexina tipo 9(pcsk9).
CA2920899C (en) 2013-08-28 2023-02-28 Sangamo Biosciences, Inc. Compositions for linking dna-binding domains and cleavage domains
JP6633532B2 (ja) * 2013-11-04 2020-01-22 ダウ アグロサイエンシィズ エルエルシー 最適なトウモロコシ遺伝子座
CN105980395A (zh) * 2013-11-04 2016-09-28 美国陶氏益农公司 最优大豆座位
ES2721936T3 (es) * 2013-11-13 2019-08-06 Childrens Medical Center Regulación de la expresión genética mediada por las nucleasas
CA3229275A1 (en) 2013-12-09 2015-06-18 Sangamo Biosciences, Inc. Methods and compositions for genome engineering
BR112016025849A2 (pt) * 2014-05-08 2017-10-17 Chdi Foundation Inc métodos e composições para o tratamento da doença de huntington
WO2015175642A2 (en) * 2014-05-13 2015-11-19 Sangamo Biosciences, Inc. Methods and compositions for prevention or treatment of a disease
US10143760B2 (en) 2015-10-28 2018-12-04 Sangamo Therapeutics, Inc. Liver-specific constructs, factor VIII expression cassettes and methods of use thereof
US11352631B2 (en) 2015-12-18 2022-06-07 Sangamo Therapeutics, Inc. Targeted disruption of the T cell receptor
JP7012650B2 (ja) 2016-02-02 2022-01-28 サンガモ セラピューティクス， インコーポレイテッド Ｄｎａ結合ドメインと切断ドメインとを連結するための組成物
IL264792B2 (en) 2016-08-24 2023-10-01 Sangamo Therapeutics Inc Engineered target-specific zinc-finger nucleases

Similar Documents

Publication Publication Date Title
JP7698828B2 (ja) Ｒｎａを編集する方法および組成物
Xu et al. Empower multiplex cell and tissue-specific CRISPR-mediated gene manipulation with self-cleaving ribozymes and tRNA
Hermant et al. TFs for TEs: the transcription factor repertoire of mammalian transposable elements
US20240336892A1 (en) Compositions and methods for the induction and tuning of gene expression
Mueller et al. PAPD5/7 are host factors that are required for hepatitis B virus RNA stabilization
Krasnopolsky et al. Genome-wide CRISPR knockout screen identifies ZNF304 as a silencer of HIV transcription that promotes viral latency
Law et al. HELLS regulates chromatin remodeling and epigenetic silencing of multiple tumor suppressor genes in human hepatocellular carcinoma
WO2020074001A1 (en) Methods and Compositions for Editing RNAs
Limsirichai et al. CRISPR-mediated activation of latent HIV-1 expression
Liu et al. Cytoplasmic viral RNA-dependent RNA polymerase disrupts the intracellular splicing machinery by entering the nucleus and interfering with Prp8
US20200010519A1 (en) Nuclease fusions for enhancing genome editing by homology-directed transgene integration
JP2021526858A5 (enExample)
Sharathchandra et al. IRES mediated translational regulation of p53 isoforms
González-Almela et al. The initiation factors eIF2, eIF2A, eIF2D, eIF4A, and eIF4G are not involved in translation driven by hepatitis C virus IRES in human cells
JP2016537341A5 (enExample)
ATE527347T1 (de) Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
JP2018530336A5 (enExample)
JP2020513784A5 (enExample)
JP2019536462A5 (enExample)
Bhat et al. HBV cccDNA—a culprit and stumbling block for the hepatitis B virus infection: its presence in hepatocytes perplexed the possible mission for a functional cure
Wu et al. NgAgo-gDNA system efficiently suppresses hepatitis B virus replication through accelerating decay of pregenomic RNA
BR112021007403A2 (pt) Composições e métodos para entrega de transgenes
KR20260032655A (ko) Hbv 유전자 발현의 후성유전학적 조절을 위한 조성물 및 방법
CL2021002226A1 (es) Transactivadores de dominios de unión a adn y usos de estos
Kermi et al. Disrupting mechanisms that regulate genomic repeat elements to combat cancer and drug resistance